Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy
Acid Reflux Esophagitis, Non-acid Reflux Esophagitis
About this trial
This is an interventional treatment trial for Acid Reflux Esophagitis focused on measuring Bile reflux, Reflux esophagitis, Lanreotide autogel, Somatuline, Endoscopy, Impedancemetry
Eligibility Criteria
Inclusion Criteria:
- Persistent endoscopic reflux in spite of maximal medical therapy with PPI 2 x 40 mg (before breakfast and dinner) and 300 mg of H2 blocker ranitidine (at bedtime).
The Los Angeles classification (LA) will be used to evaluate endoscopic reflux. Any distal esophageal ulcer with negative biopsy is also diagnostic for reflux.
Persistent reflux is defined as:
No reflux complaints but continuing endoscopic lesions and positive impedancemetry.
Reflux complaints with continuing endoscopic lesions and positive impedancemetry.
Reflux complaints without endoscopic lesions but positive impedancemetry.
Exclusion Criteria:
- Pregnancy or inadequate anticonception, breast feeding.
- Negative impedancemetry.
- Diabetes.
- Placement of a gastric ring for weight loss.
Sites / Locations
- University Hospital of Brussels
Arms of the Study
Arm 1
Experimental
Lanreotide
Lanreotide autogel 120mg injection every 4 weeks (every patient will receive 3 injections)